PCDHGA7

Across TCGA pan-cancer cohorts, PCDHGA7 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated PCDHGA7 data layer compared with 9 for mutation status.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PCDHGA7 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHGA7 expression acts as an unfavorable survival marker, although some lineages such as MESO and LIHC show a favorable association.

BLCA, CESC, and LUSC are the cancer types where PCDHGA7 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	All	0.168	0.726	<.001	88	view →
CESC	DFS	Tertile	All	0.756	0.889	.001	54	view →
LUSC	OS	Quartile	III,IV	0.527	0.862	<.001	48	view →
MESO	OS	Median	All	0.719	0.302	.003	27	view →
STAD	OS	Median	All	0.519	0.646	.003	26	view →
BRCA	DFS	Tertile	II,III,IV	0.343	0.578	.005	24	view →
LIHC	OS	Tertile	III,IV	0.633	0.171	<.001	14	view →
KIRP	DFS	Tertile	All	0.956	0.640	.022	10	view →
CHOL	DFS	Median	III,IV	0.127	0.647	.006	9	view →
DLBC	DFS	Median	All	1.000	0.649	.024	8	view →
KIRC	DFS	Tertile	IV	0.699	0.443	.021	8	view →
LAML	DFS	Quartile	All	0.661	0.291	.019	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

PCDHGA7–BLCA (OS)

Open the BLCA breakdown →